Endocrine was the most common type of immune manifestation with anti-PD-1, followed by anti-CTLA-4 and the association of both. However, with anti-PD-L1 the majority of the events were skin manifestations, although this was not a frequent prescription to our cancer patients. This evidence concerns the gene CTLA4 and cancer.